News Article

Pharmaceutical Research Firm Receives a Phase I SBI R Grant from NIH
Date: May 01, 2013
Author: press release
Source: Company Data ( click here to go to the source)

Featured firm in this article: 21st Century Therapeutics Inc of Detroit, MI



Ferndale based 21
st
Century Therapeutics, Inc. (21CTI) received a one-
year research grant of $276 K from National
Institutes of Health (NIH) to study a small-molecul
e Tumor Necrosis Factor-
α
(TNF-
α
) to treat oxaplatin-induced
thrombocytopenia. According to 21CTI's CEO, Dr. Fre
derick Valeriote, this is the fourth SBIR grant rec
eived by
21CTI.
"This research grant will help us further the precl
inical development of UTL-5g as a chemoprotector",
said Valeriote.
According to 21CTI's president and the Principal In
vestigator of this study, Dr. JJ Shaw, oxaliplatin
is a platinum
drug that is more widely prescribed than cisplatin.
Our recent studies showed that pretreatment of UTL
-5g
restored/increased platelet number reduced by cispl
atin. Therefore, this Phase I SBIR grant will be us
ed to show the
feasibility of using UTL-5g to treat thrombocytopen
ia induced by oxaliplatin. If successful, a Phase I
I grant will be
applied to continue the preclinical development.
21CTI is a private pharmaceutical discovery and dev
elopment company, specializing in cancer and immune
-
mediated diseases. In addition to this project, the
Company has several projects under discovery or de
velopment,
This release contains forward-looking statements th
at are subject to various risks and uncertainties.
Actual results
could differ materially from those described in the
se forward-looking statements due to certain factor
s, including
changes in business, economic and competitive condi
tions, regulatory reforms, foreign exchanges rate f
luctuations,
uncertainties in litigation or investigative procee
dings, and the availability of financing. 21CTI's m
anagement does
not undertake any responsibility to update the forw
ard-looking statements contained in this release.
Contact: Office (248) 545-0595, Frederick Valeriote
(586) 863-8298, JJ Shaw (734) 330-6052
Website: www.21-cti.com
e-mail:
jshaw@21-cti.com
or
jiajiushaw@gmail.com